In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2576-2578

  Karlowsky, James A ^a,b,c   Harding, Gary A J ^c   Zelenitsky, Sheryl A ^a   Hoban, Daryl J ^b,c   Kabani, Amin ^b,c   Balko, Tamara V ^b   Turik, Michael ^d   Zhanel, George G ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDIASIS; DOSE RESPONSE; DRUG SENSITIVITY; FUNGUS CULTURE; FUNGUS GROWTH; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030685788     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2576     Document Type: Article

References (15)

1. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Tolson, T. Henderson, W. J. Henderson, and W. J. Marone. 1991. Secular trends in nosocomial primary bloodstream infections in the United States 1980-1989. Am. J. Med. 91(Suppl. 3B):86S-89S.
2. Current, W. L., C. J. Boylan, and P. P. Raab. 1993. Anti-Pneumocystis activity of LY-303366 and other echinocandin B analogs, abstr. 368, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Debono, M. 1994. The echinocandins: antifungals targeted to the fungal cell wall. Exp. Opin. Invest. Drugs 3:821-829.
4. Ernst, M. E., M. E. Klepser, E. J. Wolfe, and M. A. Pfaller. 1996. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn. Microbiol. Infect. Dis. 26:125-131.
5. Gooday, G. W. 1995. The potential of novel antifungal drugs for the treatment of disease in the immunocompromised host. Exp. Opin. Invest. Drugs 4:679-691.
6. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeast. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
7. Pfaller, M. A., S. Messer, and S. Coffman. 1996. In vitro susceptibility of Candida blood stream isolates to a new echinocandin derivative, LY303366, and comparative antifungal agents, abstr. F48, p. 108. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Pfaller, M., and R. Wenzel. 1992. Impact of changing epidemiology of fungal infections in the 1990's. Eur. J. Clin. Microbiol. Infect. Dis. 11:287-291.
9. Rennie, R., C. Sand, and S. Smith. 1996. In vitro activity of antifungal agent LY303366 against Candida species, other yeasts and Aspergillus species, abstr. F45, p. 107. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Stevens, D. A., M. Martinez, and M. J. Devine. 1996. Antifungal activity of LY303366 (LY), an echinocandin beta glucan synthase inhibitor (GSI), abstr. F46, p. 107. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Vanden Bossche, H., D. W. Warnock, B. Dupont, D. Kerridge, S. Sen Gupta, L. Improvisi, P. Marichal, F. C. Odds, F. Provost, and O. Ronin. 1994. Mechanisms and clinical impact of antifungal resistance. J. Med. Vet. Mycol. 32(Suppl. 1):189-202.
12. Zeckner, D., T. Butler, C. Boylan, B. Boyll, Y. Lin, P. Raab, J. Schmidtke, and W. Current. 1993. LY-303366, activity against systemic aspergillosis and histoplasmosis in murine models, abstr. 364, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Zeckner, D., T. Butler, C. Boylan, B. Boyll, Y. Lin, P. Raab, J. Schmidtke, and W. Current. 1993. LY-303366, activity in a murine systemic candidiasis model, abstr. 365, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Zeckner, D., T. Butler, C. Boylan, B. Boyll, P. Watson, and W. Current. 1995. In vitro evaluation of LY303366 against Candida spp. clinical isolates and evaluation of efficacy in a murine model of systemic candidiasis, abstr. F98, p. 130. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Zhanel, G. G., J. A. Karlowsky, G. A. J. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.